Clin2
NCT06674460Possibly a fitRecruiting

Edaravone Dexborneol tablet for stroke recovery

Cerebral Small Vessel DiseaseIschemic Stroke

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests a new sublingual tablet (Edaravone Dexborneol) to help people recover after a small stroke caused by disease of the small blood vessels in the brain. It aims to see if the drug can improve thinking and daily function.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
600 people
Ages
30 years to 80 years
Study type
Interventional

Who can take part

  • You are between 30 and 80 years old.
  • You had a small stroke in the deep brain areas confirmed by MRI.
  • Your stroke started less than 3 weeks ago.
  • You had little or no disability before the stroke (able to do daily activities independently).
  • You have no previous diagnosis of dementia or cognitive problems.
  • You are able to complete thinking and memory tests (at least primary school education).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07119021Recruiting· Phase 4
Ultra-early stroke treatment with neuroprotection and clot removal

This trial tests a new approach for treating acute ischemic stroke within 4.5 hours of symptoms starting. It combines a special mobile stroke unit that delivers early brain-protecting medicine with standard clot-busting or clot-removal procedures, to see if this can improve recovery.

Beijing
NCT06712004Recruiting· Phase 2
Testing a new stroke drug: different doses for people who cannot get standard care

This trial tests a new medication (bevifibatide) to see which dose works best for people having an ischemic stroke who cannot get standard treatments like clot-busting drugs or a procedure to remove the clot. It aims to improve recovery by stopping clots from getting worse.

Guangzhou, Guangdong
NCT06660719Recruiting· Phase 3
New stroke medicine SP-8203 with clot-busting therapy

This trial tests a new medicine called SP-8203 added to standard clot-busting treatment for people having a moderate to severe stroke. The goal is to see if it helps improve recovery and is safe.

Busan
NCT06315231Recruiting· Phase 2
Stroke Recovery Thinking Trial for Recent Stroke Patients

This study tests an under-the-tongue tablet (edaravone dexborneol) to help thinking and memory problems that can happen after an ischemic stroke. It may help people who recently had a stroke and now have trouble with attention, memory, or planning.

Fuyang, Anhui
NCT06645522Not yet recruiting· Phase 4
Study of edaravone dexborneol for acute stroke

This trial tests a medicine called edaravone dexborneol for people who have had an acute ischemic stroke (a stroke caused by a blood clot). The goal is to see if it is safe and helps improve recovery when given within 48 hours of the stroke starting.

Changchun, Jilin
NCT07604350Not yet recruiting· Phase 3
Edaravone Dexborneol to Prevent Seizures After Stroke

This study tests whether a combination medicine (edaravone dexborneol) can prevent seizures in people who have just had an ischemic stroke (a stroke caused by a blood clot). You would receive this medicine within 48 hours of your stroke if you're at high risk for developing seizures.

Wenzhou, Zhejiang

Hear when a new Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.